Observational analysis showing safety and treatment discontinuations in patients receiving axatilimab for cGVHD, suggesting feasibility of a new dosing strategy.
Key Points
Axatilimab, a monoclonal antibody, demonstrates safety and efficacy in chronic graft-versus-host disease (cGVHD).
Seventy-three percent of patients achieved a response, with a reported overall response rate of 94.7% after switching doses.
This assessment involved patients transitioning from a 0.3 mg/kg Q2W to 0.6 mg/kg Q4W dosing schedule over several cycles.
Findings call for careful consideration of dosing schedules for improved safety and continued treatment in cGVHD patients.